Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:VRTX
- CUSIP: 92532F10
- Web: www.vrtx.com
Capitalization:- Market Cap: $37.34639 billion
- Outstanding Shares: 252,118,000
Average Prices:- 50 Day Moving Avg: $146.73
- 200 Day Moving Avg: $117.81
- 52 Week Range: $71.46 - $167.86
P/E:- Trailing P/E Ratio: 143.82
- Foreward P/E Ratio: 77.15
- P/E Growth: 1.36
Sales & Book Value:- Annual Revenue: $2.13 billion
- Price / Sales: 17.53
- Book Value: $6.66 per share
- Price / Book: 22.24
Profitability:- EBIDTA: $408.78 million
- Net Margins: 12.05%
- Return on Equity: 4.64%
- Return on Assets: 2.41%
Debt:- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 3.49%
- Quick Ratio: 3.34%
Misc:- Average Volume: 2.03 million shs.
- Beta: 1.77
- Short Ratio: 1.32
Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
What is Vertex Pharmaceuticals Incorporated's stock symbol?
Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."
How were Vertex Pharmaceuticals Incorporated's earnings last quarter?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its earnings results on Wednesday, July, 26th. The company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.33. The firm had revenue of $544.10 million for the quarter, compared to the consensus estimate of $489.95 million. Vertex Pharmaceuticals Incorporated had a return on equity of 4.64% and a net margin of 12.05%. The company's revenue was up 26.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.24 earnings per share. View Vertex Pharmaceuticals Incorporated's Earnings History.
When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?
Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?
24 brokers have issued 12 month target prices for Vertex Pharmaceuticals Incorporated's stock. Their forecasts range from $81.00 to $200.00. On average, they expect Vertex Pharmaceuticals Incorporated's share price to reach $162.41 in the next year. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.
What are analysts saying about Vertex Pharmaceuticals Incorporated stock?
Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:
- 1. According to Zacks Investment Research, "Vertex beat estimates for both earnings and sales in Q2 as sales of both its cystic fibrosis (CF) drugs rose. Vertex has two CF drugs in its portfolio with blockbuster potential – Kalydeco & Orkambi. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase patient population and boost sales. Vertex’s CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on the triple combination CF regimens, which are crucial for long-term growth as they have the potential to treat up to 90% of CF patients. We are encouraged by the recent positive data from three of the triple combination regimens. The stock has also shot up this year. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Orkambi’s EU reimbursement remains a key for sales growth in 2H17." (8/4/2017)
- 2. Cowen and Company analysts commented, "Vertex announced that the FDA has approved Kalydeco for use in CF patients over the." (8/1/2017)
- 3. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)
- 4. Maxim Group analysts commented, "Vertex reported 1Q17 with total CF revenue of $481M, which was above consensus of $444M, driven by both Orkambi and Kalydeco revenues beating estimates." (4/28/2017)
Who are some of Vertex Pharmaceuticals Incorporated's key competitors?
Some companies that are related to Vertex Pharmaceuticals Incorporated include Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Kite Pharma (KITE), TESARO (TSRO), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT) and Spark Therapeutics (ONCE).
Who are Vertex Pharmaceuticals Incorporated's key executives?
Vertex Pharmaceuticals Incorporated's management team includes the folowing people:
- Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
- Ian F. Smith CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President
- Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer
- David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer
- Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer
- Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
- Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
- Paul M. Silva, Senior Vice President, Corporate Controller
- Bruce I. Sachs, Lead Director, Independent Director
- Elaine S. Ullian, Co-Lead Independent Director
Who owns Vertex Pharmaceuticals Incorporated stock?
Vertex Pharmaceuticals Incorporated's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.70%), FMR LLC (7.33%), Vanguard Group Inc. (6.73%), Capital World Investors (6.11%), State Street Corp (4.51%) and JPMorgan Chase & Co. (3.32%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.
Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?
Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Ameriprise Financial Inc., JPMorgan Chase & Co., State Street Corp, HealthCor Management L.P., FMR LLC, Lazard Asset Management LLC and Laurion Capital Management LP. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.
Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?
Vertex Pharmaceuticals Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Old Mutual Global Investors UK Ltd., AJO LP, Vanguard Group Inc., TIAA CREF Investment Management LLC, Fred Alger Management Inc., Janus Henderson Group PLC and Columbus Circle Investors. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.
How do I buy Vertex Pharmaceuticals Incorporated stock?
Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vertex Pharmaceuticals Incorporated's stock price today?
One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $148.13.
MarketBeat Community Rating for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 21 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.88) |
| Consensus Price Target: | $162.41 (9.64% upside) |
Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/1/2017 | Cowen and Company | Reiterated Rating | Buy | | Medium |  |
| 8/1/2017 | Argus | Boost Price Target | Buy | $71.46 -> $175.00 | Low | |
| 7/27/2017 | BMO Capital Markets | Reiterated Rating | Outperform | $180.00 -> $182.00 | Low | |
| 7/27/2017 | Oppenheimer Holdings, Inc. | Boost Price Target | Outperform | $150.00 -> $175.00 | Medium | |
| 7/27/2017 | J P Morgan Chase & Co | Set Price Target | Buy | $175.00 -> $184.00 | High | |
| 7/27/2017 | Maxim Group | Set Price Target | Buy | $195.00 | High | |
| 7/22/2017 | Morgan Stanley | Reiterated Rating | Overweight | $153.00 -> $190.00 | Low | |
| 7/21/2017 | Robert W. Baird | Reiterated Rating | Outperform | $136.00 -> $171.00 | Low | |
| 7/21/2017 | Needham & Company LLC | Reiterated Rating | Buy | $155.00 -> $195.00 | Low | |
| 7/21/2017 | Citigroup Inc. | Reiterated Rating | Buy | $135.00 -> $190.00 | Low | |
| 7/19/2017 | Credit Suisse Group | Boost Price Target | Outperform | $125.00 -> $195.00 | High | |
| 7/19/2017 | JMP Securities | Reiterated Rating | Outperform | | High | |
| 7/19/2017 | Raymond James Financial, Inc. | Upgrade | Market Perform -> Outperform | $181.00 | High | |
| 7/19/2017 | Piper Jaffray Companies | Boost Price Target | Overweight | $194.00 | High | |
| 7/19/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $155.00 -> $185.00 | High | |
| 7/19/2017 | HC Wainwright | Reiterated Rating | Hold | $85.00 | High | |
| 7/19/2017 | Janney Montgomery Scott | Upgrade | Neutral -> Buy | $98.00 | High | |
| 7/19/2017 | Barclays PLC | Upgrade | Equal Weight -> Overweight | $115.00 -> $180.00 | High | |
| 7/18/2017 | Stifel Nicolaus | Boost Price Target | Buy -> Buy | $130.00 -> $154.00 | High | |
| 6/22/2017 | Leerink Swann | Reiterated Rating | Outperform | | Medium | |
| 6/2/2017 | CIBC | Upgrade | Market Perform -> Outperform | | Low | |
| 5/19/2017 | Bank of America Corporation | Reiterated Rating | Neutral | $121.00 -> $125.00 | Low | |
| 11/1/2016 | William Blair | Downgrade | Outperform -> Market Perform | $105.00 -> $81.00 | N/A | |
| 10/12/2016 | Royal Bank Of Canada | Reiterated Rating | Buy | | N/A | |
| 4/28/2016 | Goldman Sachs Group, Inc. (The) | Downgrade | Buy -> Neutral | $109.00 -> $88.00 | N/A | |
| 3/28/2016 | Guggenheim | Lower Price Target | Buy | $145.00 -> $114.00 | N/A | |
| 9/15/2015 | Nomura | Initiated Coverage | Buy | $162.00 | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/23/2017 | | $0.40 | | | | | N/A | |
| 7/26/2017 | Q2 2017 | $0.06 | $0.39 | $489.95 million | $544.10 million | View | N/A | |
| 4/27/2017 | Q1 2017 | $0.04 | $0.13 | $692.64 million | $714.72 million | View | N/A | |
| 1/25/2017 | Q4 2016 | $0.29 | $0.35 | $453.40 million | $458.71 million | View | N/A | |
| 10/25/2016 | Q316 | $0.18 | $0.16 | $423.53 million | $413.78 million | View | Listen | |
| 7/27/2016 | Q216 | $0.21 | $0.24 | $428.08 million | $431.61 million | View | Listen | |
| 4/27/2016 | Q116 | $0.29 | $0.09 | $439.94 million | $398.10 million | View | Listen | |
| 1/27/2016 | Q4 | $0.17 | $0.17 | $406.30 million | $417.94 million | View | Listen | |
| 10/28/2015 | Q315 | ($0.60) | ($0.13) | $245.84 million | $309.82 million | View | Listen | |
| 7/29/2015 | Q215 | ($0.58) | ($0.54) | $149.49 million | $166.00 million | View | Listen | |
| 4/29/2015 | Q115 | ($0.75) | ($0.62) | $142.38 million | $138.51 million | View | Listen | |
| 1/28/2015 | Q414 | ($0.65) | ($0.55) | $137.50 million | $144.56 million | View | Listen | |
| 10/28/2014 | Q314 | ($0.62) | ($0.37) | $146.20 million | $179.00 million | View | N/A | |
| 7/29/2014 | Q214 | ($0.71) | ($0.61) | $131.85 million | $138.42 million | View | Listen | |
| 5/1/2014 | Q114 | ($0.68) | ($0.65) | $134.46 million | $118.50 million | View | N/A | |
| 1/29/2014 | Q413 | ($0.49) | ($0.56) | $221.08 million | $351.20 million | View | Listen | |
| 10/29/2013 | Q413 | ($0.33) | ($0.32) | $278.80 million | $222.00 million | View | N/A | |
| 7/29/2013 | Q2 2013 | ($0.18) | ($0.26) | $308.02 million | $310.80 million | View | N/A | |
| 4/30/2013 | Q1 2013 | ($0.06) | $0.03 | $307.85 million | $328.40 million | View | N/A | |
| 1/29/2013 | Q4 2012 | ($0.07) | ($0.35) | $318.53 million | $334.00 million | View | N/A | |
| 11/1/2012 | Q312 | $0.34 | $0.13 | $377.14 million | $336.00 million | View | N/A | |
| 7/30/2012 | | $0.68 | $0.46 | | | View | N/A | |
| 4/26/2012 | | $0.57 | $0.43 | | | View | N/A | |
| 2/2/2012 | | $0.76 | $0.74 | | | View | N/A | |
| 10/27/2011 | | $0.17 | $0.70 | | | View | N/A | |
| 7/28/2011 | | ($1.00) | ($0.67) | | | View | N/A | |
| 5/3/2011 | | ($1.09) | ($0.91) | | | View | N/A | |
| 2/3/2011 | | ($0.93) | ($0.74) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)2017 EPS Consensus Estimate: $0.56
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($0.02) | $0.04 | $0.02 |
| Q2 2017 | 4 | $0.02 | $0.11 | $0.07 |
| Q3 2017 | 3 | $0.07 | $0.11 | $0.09 |
| Q4 2017 | 3 | $0.26 | $0.56 | $0.38 |
(Data provided by Zacks Investment Research)
Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 1/29/2013 | quarterly | $0.40 | | | 2/20/2013 | 3/13/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 94.89%
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/7/2017 | Ian F Smith | CFO | Sell | 4,250 | $155.39 | $660,407.50 | |
| 8/7/2017 | Paul M Silva | SVP | Sell | 1,289 | $152.88 | $197,062.32 | |
| 8/3/2017 | Jeffrey Chodakewitz | CMO | Sell | 5,390 | $154.17 | $830,976.30 | |
| 8/3/2017 | Michael Parini | EVP | Sell | 2,330 | $155.72 | $362,827.60 | |
| 8/2/2017 | Ian F Smith | CFO | Sell | 2,155 | $154.17 | $332,236.35 | |
| 8/2/2017 | Jeffrey Chodakewitz | CMO | Sell | 1,796 | $154.13 | $276,817.48 | |
| 8/2/2017 | Paul M Silva | SVP | Sell | 1,289 | $151.80 | $195,670.20 | |
| 7/31/2017 | Jeffrey M Leiden | CEO | Sell | 11,063 | $152.81 | $1,690,537.03 | |
| 7/31/2017 | Paul M Silva | SVP | Sell | 860 | $152.99 | $131,571.40 | |
| 7/31/2017 | Stuart A Arbuckle | EVP | Sell | 2,125 | $152.99 | $325,103.75 | |
| 7/21/2017 | Amit Sachdev | EVP | Sell | 28,625 | $160.93 | $4,606,621.25 | |
| 7/21/2017 | Ian F Smith | CFO | Sell | 133,750 | $160.98 | $21,531,075.00 | |
| 7/21/2017 | Jeffrey Chodakewitz | CMO | Sell | 46,733 | $160.96 | $7,522,143.68 | |
| 7/21/2017 | Jeffrey M Leiden | CEO | Sell | 216,624 | $160.96 | $34,867,799.04 | |
| 7/21/2017 | Paul M Silva | SVP | Sell | 43,443 | $161.07 | $6,997,364.01 | |
| 7/19/2017 | Michael Parini | EVP | Sell | 10,829 | $161.00 | $1,743,469.00 | |
| 7/17/2017 | Jeffrey Chodakewitz | CMO | Sell | 573 | $129.85 | $74,404.05 | |
| 7/3/2017 | Jeffrey Chodakewitz | CMO | Sell | 3,438 | $127.80 | $439,376.40 | |
| 6/21/2017 | Jeffrey Chodakewitz | CMO | Sell | 5,157 | $132.87 | $685,210.59 | |
| 6/21/2017 | Paul M Silva | SVP | Sell | 2,577 | $133.36 | $343,668.72 | |
| 6/5/2017 | David Altshuler | EVP | Sell | 7,500 | $130.00 | $975,000.00 | |
| 6/2/2017 | Jeffrey M Leiden | CEO | Sell | 147,101 | $129.50 | $19,049,579.50 | |
| 6/2/2017 | Sangeeta N Bhatia | Director | Sell | 1,176 | $128.44 | $151,045.44 | |
| 6/2/2017 | Stuart A Arbuckle | EVP | Sell | 70,969 | $128.06 | $9,088,290.14 | |
| 5/2/2017 | Jeffrey Chodakewitz | CMO | Sell | 8,979 | $121.05 | $1,086,907.95 | |
| 4/28/2017 | Jeffrey M Leiden | CEO | Sell | 157,200 | $119.50 | $18,785,400.00 | |
| 4/5/2017 | Jeffrey Chodakewitz | CMO | Sell | 8,021 | $114.00 | $914,394.00 | |
| 4/3/2017 | Jeffrey Chodakewitz | CMO | Sell | 2,291 | $108.85 | $249,375.35 | |
| 3/29/2017 | Amit Sachdev | EVP | Sell | 80,500 | $107.63 | $8,664,215.00 | |
| 3/29/2017 | Jeffrey Chodakewitz | CMO | Sell | 13,750 | $106.65 | $1,466,437.50 | |
| 3/29/2017 | Paul M Silva | SVP | Sell | 1,688 | $106.30 | $179,434.40 | |
| 1/11/2017 | Joshua S Boger | Director | Sell | 8,000 | $82.48 | $659,840.00 | |
| 1/4/2017 | Joshua S Boger | Director | Sell | 6,500 | $77.13 | $501,345.00 | |
| 12/29/2016 | Joshua S Boger | Director | Sell | 6,500 | $74.33 | $483,145.00 | |
| 12/21/2016 | Joshua S Boger | Director | Sell | 6,500 | $74.16 | $482,040.00 | |
| 12/14/2016 | Joshua S Boger | Director | Sell | 6,500 | $77.52 | $503,880.00 | |
| 11/30/2016 | Joshua S Boger | Director | Sell | 6,500 | $83.48 | $542,620.00 | |
| 11/23/2016 | Joshua S Boger | Director | Sell | 6,500 | $86.47 | $562,055.00 | |
| 11/16/2016 | Joshua S Boger | Director | Sell | 6,500 | $91.55 | $595,075.00 | |
| 11/10/2016 | Paul M Silva | SVP | Sell | 5,062 | $90.98 | $460,540.76 | |
| 11/9/2016 | Joshua S Boger | Director | Sell | 6,500 | $90.98 | $591,370.00 | |
| 11/9/2016 | Stuart A Arbuckle | EVP | Sell | 1,208 | $90.00 | $108,720.00 | |
| 11/2/2016 | Joshua S Boger | Director | Sell | 6,500 | $77.75 | $505,375.00 | |
| 10/26/2016 | Joshua S Boger | Director | Sell | 6,500 | $79.26 | $515,190.00 | |
| 10/19/2016 | Joshua S Boger | Director | Sell | 6,500 | $81.84 | $531,960.00 | |
| 10/12/2016 | Joshua S Boger | Director | Sell | 6,500 | $81.14 | $527,410.00 | |
| 10/5/2016 | Joshua S Boger | Director | Sell | 6,500 | $87.44 | $568,360.00 | |
| 10/3/2016 | Stuart A Arbuckle | EVP | Sell | 1,208 | $86.46 | $104,443.68 | |
| 9/28/2016 | Joshua S Boger | Director | Sell | 6,500 | $88.15 | $572,975.00 | |
| 9/21/2016 | Joshua S Boger | Director | Sell | 6,500 | $90.82 | $590,330.00 | |
| 9/14/2016 | Joshua S Boger | Director | Sell | 6,500 | $92.37 | $600,405.00 | |
| 9/7/2016 | Joshua S Boger | Director | Sell | 6,500 | $95.66 | $621,790.00 | |
| 8/31/2016 | Joshua S Boger | Director | Sell | 6,500 | $94.62 | $615,030.00 | |
| 8/24/2016 | Joshua S Boger | Director | Sell | 7,500 | $100.46 | $753,450.00 | |
| 8/22/2016 | Joshua S Boger | Director | Sell | 1,100 | $100.79 | $110,869.00 | |
| 8/17/2016 | Joshua S Boger | Director | Sell | 6,900 | $99.63 | $687,447.00 | |
| 8/11/2016 | Joshua S Boger | Director | Sell | 900 | $100.19 | $90,171.00 | |
| 8/10/2016 | Joshua S Boger | Director | Sell | 7,100 | $100.24 | $711,704.00 | |
| 8/3/2016 | Joshua S Boger | Director | Sell | 47,000 | $100.66 | $4,731,020.00 | |
| 7/27/2016 | Joshua S Boger | Director | Sell | 6,500 | $95.93 | $623,545.00 | |
| 7/20/2016 | Joshua S Boger | Director | Sell | 6,500 | $90.33 | $587,145.00 | |
| 7/13/2016 | Joshua S Boger | Director | Sell | 6,500 | $88.81 | $577,265.00 | |
| 7/6/2016 | Joshua S Boger | Director | Sell | 5,140 | $88.99 | $457,408.60 | |
| 6/29/2016 | Joshua S Boger | Director | Sell | 5,130 | $84.82 | $435,126.60 | |
| 6/22/2016 | Joshua S Boger | Director | Sell | 5,130 | $86.61 | $444,309.30 | |
| 6/15/2016 | Joshua S Boger | Director | Sell | 5,130 | $91.18 | $467,753.40 | |
| 6/8/2016 | Joshua S Boger | Director | Sell | 5,130 | $94.95 | $487,093.50 | |
| 6/1/2016 | Joshua S Boger | Director | Sell | 5,130 | $93.65 | $480,424.50 | |
| 5/25/2016 | Joshua S Boger | Director | Sell | 5,130 | $89.09 | $457,031.70 | |
| 5/18/2016 | Joshua S Boger | Director | Sell | 5,130 | $81.18 | $416,453.40 | |
| 5/16/2016 | Amit Sachdev | EVP | Sell | 117 | $81.67 | $9,555.39 | |
| 5/16/2016 | Ian F Smith | CFO | Sell | 202 | $82.06 | $16,576.12 | |
| 5/11/2016 | Joshua S Boger | Director | Sell | 5,130 | $86.50 | $443,745.00 | |
| 5/9/2016 | Paul M Silva | SVP | Sell | 3,000 | $87.63 | $262,890.00 | |
| 5/4/2016 | Joshua S Boger | Director | Sell | 5,130 | $81.02 | $415,632.60 | |
| 4/27/2016 | Joshua S Boger | Director | Sell | 5,130 | $83.67 | $429,227.10 | |
| 4/20/2016 | Joshua S Boger | Director | Sell | 5,130 | $84.10 | $431,433.00 | |
| 4/13/2016 | Joshua S Boger | Director | Sell | 5,130 | $84.27 | $432,305.10 | |
| 4/6/2016 | Joshua S Boger | Director | Sell | 5,130 | $89.56 | $459,442.80 | |
| 3/30/2016 | Joshua S Boger | Director | Sell | 5,130 | $78.83 | $404,397.90 | |
| 3/23/2016 | Joshua S Boger | Director | Sell | 5,130 | $81.38 | $417,479.40 | |
| 3/16/2016 | Joshua S Boger | Director | Sell | 5,130 | $79.65 | $408,604.50 | |
| 3/2/2016 | Joshua S Boger | Director | Sell | 5,130 | $91.80 | $470,934.00 | |
| 2/24/2016 | Joshua S Boger | Director | Sell | 5,130 | $85.25 | $437,332.50 | |
| 2/17/2016 | Joshua S. Boger | Director | Sell | 5,130 | $86.93 | $445,950.90 | |
| 2/10/2016 | Joshua S. Boger | Director | Sell | 5,130 | $82.57 | $423,584.10 | |
| 2/3/2016 | Ian F. Smith | CFO | Sell | 12,084 | $90.84 | $1,097,710.56 | |
| 2/3/2016 | Jeffrey M. Leiden | CEO | Sell | 9,834 | $90.82 | $893,123.88 | |
| 2/3/2016 | Joshua S. Boger | Director | Sell | 5,130 | $90.81 | $465,855.30 | |
| 2/3/2016 | Paul M. Silva | SVP | Sell | 5,062 | $90.82 | $459,730.84 | |
| 2/3/2016 | Stuart A. Arbuckle | EVP | Sell | 6,042 | $90.82 | $548,734.44 | |
| 2/2/2016 | Jeffrey Chodakewitz | CMO | Sell | 2,375 | $91.38 | $217,027.50 | |
| 1/27/2016 | Joshua S. Boger | Director | Sell | 11,200 | $93.22 | $1,044,064.00 | |
| 1/20/2016 | Joshua S. Boger | Director | Sell | 10,400 | $93.69 | $974,376.00 | |
| 1/13/2016 | Joshua S. Boger | Director | Sell | 10,400 | $98.41 | $1,023,464.00 | |
| 1/6/2016 | Joshua S. Boger | Director | Sell | 10,400 | $121.96 | $1,268,384.00 | |
| 1/4/2016 | Yuchun Lee | Director | Sell | 1,125 | $122.21 | $137,486.25 | |
| 12/30/2015 | Joshua S. Boger | Director | Sell | 10,400 | $127.15 | $1,322,360.00 | |
| 12/21/2015 | Joshua S. Boger | Director | Sell | 10,400 | $119.26 | $1,240,304.00 | |
| 12/9/2015 | Joshua S. Boger | Director | Sell | 10,400 | $120.80 | $1,256,320.00 | |
| 12/4/2015 | Stuart A. Arbuckle | EVP | Sell | 4,531 | $123.98 | $561,753.38 | |
| 12/2/2015 | Joshua S. Boger | Director | Sell | 10,400 | $130.91 | $1,361,464.00 | |
| 12/1/2015 | David Altshuler | EVP | Sell | 5,000 | $131.00 | $655,000.00 | |
| 12/1/2015 | Yuchun Lee | Director | Sell | 1,125 | $129.65 | $145,856.25 | |
| 11/23/2015 | Joshua S. Boger | Director | Sell | 10,400 | $132.18 | $1,374,672.00 | |
| 11/11/2015 | Joshua S. Boger | Director | Sell | 10,400 | $118.59 | $1,233,336.00 | |
| 11/4/2015 | Joshua S. Boger | Director | Sell | 10,400 | $124.23 | $1,291,992.00 | |
| 11/2/2015 | Yuchun Lee | Director | Sell | 1,125 | $126.19 | $141,963.75 | |
| 10/28/2015 | Joshua S. Boger | Director | Sell | 10,400 | $119.01 | $1,237,704.00 | |
| 10/21/2015 | Joshua S. Boger | Director | Sell | 10,400 | $108.82 | $1,131,728.00 | |
| 10/14/2015 | Joshua S. Boger | Director | Sell | 10,400 | $112.62 | $1,171,248.00 | |
| 10/7/2015 | Joshua S. Boger | Director | Sell | 10,400 | $109.61 | $1,139,944.00 | |
| 10/2/2015 | Elaine Ullian | Director | Sell | 20,000 | $110.00 | $2,200,000.00 | |
| 10/1/2015 | Stuart A. Arbuckle | EVP | Sell | 12,417 | $104.71 | $1,300,184.07 | |
| 10/1/2015 | Yuchun Lee | Director | Sell | 1,125 | $104.64 | $117,720.00 | |
| 9/30/2015 | Joshua S. Boger | Director | Sell | 10,400 | $103.14 | $1,072,656.00 | |
| 9/23/2015 | Joshua S. Boger | Director | Sell | 10,400 | $111.89 | $1,163,656.00 | |
| 9/16/2015 | Joshua S. Boger | Director | Sell | 10,400 | $133.24 | $1,385,696.00 | |
| 9/9/2015 | Joshua S. Boger | Director | Sell | 10,400 | $131.41 | $1,366,664.00 | |
| 9/4/2015 | Stuart A. Arbuckle | EVP | Sell | 9,063 | $125.77 | $1,139,853.51 | |
| 9/2/2015 | Joshua S. Boger | Director | Sell | 10,400 | $125.85 | $1,308,840.00 | |
| 9/1/2015 | Yuchun Lee | Director | Sell | 1,125 | $125.40 | $141,075.00 | |
| 8/26/2015 | Joshua S. Boger | Director | Sell | 10,400 | $124.71 | $1,296,984.00 | |
| 8/19/2015 | Joshua S. Boger | Director | Sell | 10,400 | $139.93 | $1,455,272.00 | |
| 8/12/2015 | Joshua S Boger | Director | Sell | 10,400 | $135.83 | $1,412,632.00 | |
| 7/22/2015 | Joshua S Boger | Director | Sell | 10,400 | $130.92 | $1,361,568.00 | |
| 7/15/2015 | Joshua S Boger | Director | Sell | 12,200 | $133.98 | $1,634,556.00 | |
| 7/13/2015 | Paul M Silva | SVP | Sell | 1,125 | $123.79 | $139,263.75 | |
| 7/8/2015 | Joshua S Boger | Director | Sell | 11,700 | $122.74 | $1,436,058.00 | |
| 7/2/2015 | Jeffrey Chodakewitz | CMO | Sell | 2,291 | $129.36 | $296,363.76 | |
| 7/1/2015 | Joshua S Boger | Director | Sell | 11,700 | $125.60 | $1,469,520.00 | |
| 6/24/2015 | Joshua S Boger | Director | Sell | 11,700 | $130.41 | $1,525,797.00 | |
| 6/17/2015 | Joshua S Boger | Director | Sell | 11,700 | $123.90 | $1,449,630.00 | |
| 6/10/2015 | Joshua S Boger | Director | Sell | 11,700 | $125.02 | $1,462,734.00 | |
| 5/20/2015 | Joshua S Boger | Director | Sell | 11,700 | $126.73 | $1,482,741.00 | |
| 5/6/2015 | Joshua S Boger | Director | Sell | 11,700 | $122.79 | $1,436,643.00 | |
| 5/5/2015 | Paul M Silva | SVP | Sell | 4,101 | $123.68 | $507,211.68 | |
| 4/29/2015 | Joshua S Boger | Director | Sell | 11,700 | $124.59 | $1,457,703.00 | |
| 4/27/2015 | Paul M Silva | SVP | Sell | 1,125 | $129.74 | $145,957.50 | |
| 4/27/2015 | Stuart A Arbuckle | EVP | Sell | 61,480 | $129.36 | $7,953,052.80 | |
| 4/27/2015 | Terrence C Kearney | Director | Sell | 68,125 | $129.11 | $8,795,618.75 | |
| 4/22/2015 | Joshua S Boger | Director | Sell | 11,700 | $132.46 | $1,549,782.00 | |
| 4/15/2015 | Joshua S Boger | Director | Sell | 11,700 | $129.25 | $1,512,225.00 | |
| 4/13/2015 | Paul M Silva | SVP | Sell | 1,125 | $128.60 | $144,675.00 | |
| 4/8/2015 | Joshua S Boger | Director | Sell | 11,700 | $123.26 | $1,442,142.00 | |
| 4/6/2015 | Margaret G Mcglynn | Director | Sell | 12,500 | $118.36 | $1,479,500.00 | |
| 4/2/2015 | Jeffrey Chodakewitz | CMO | Sell | 2,291 | $115.50 | $264,610.50 | |
| 4/1/2015 | Joshua S Boger | Director | Sell | 11,700 | $115.87 | $1,355,679.00 | |
| 3/25/2015 | Joshua S Boger | Director | Sell | 11,700 | $120.76 | $1,412,892.00 | |
| 3/23/2015 | Amit Sachdev | EVP | Sell | 17,083 | $132.28 | $2,259,739.24 | |
| 3/23/2015 | Ian F Smith | CFO | Sell | 6,042 | $125.67 | $759,298.14 | |
| 3/23/2015 | Paul M Silva | SVP | Sell | 2,250 | $125.65 | $282,712.50 | |
| 3/18/2015 | Amit Sachdev | EVP | Sell | 12,000 | $130.00 | $1,560,000.00 | |
| 2/5/2015 | Paul M Silva | SVP | Sell | 1,688 | $109.75 | $185,258.00 | |
| 2/4/2015 | Joshua S Boger | Director | Sell | 5,700 | $108.81 | $620,217.00 | |
| 2/3/2015 | Paul M Silva | SVP | Sell | 2,063 | $108.89 | $224,640.07 | |
| 2/2/2015 | Jeffrey Chodakewitz | CMO | Sell | 1,188 | $109.60 | $130,204.80 | |
| 1/28/2015 | Joshua S Boger | Director | Sell | 10,688 | $122.78 | $1,312,272.64 | |
| 1/26/2015 | Paul M Silva | SVP | Sell | 1,125 | $125.62 | $141,322.50 | |
| 1/21/2015 | Joshua S Boger | Director | Sell | 10,500 | $125.08 | $1,313,340.00 | |
| 1/14/2015 | Joshua S Boger | Director | Sell | 10,500 | $120.16 | $1,261,680.00 | |
| 1/9/2015 | Amit Sachdev | EVP | Sell | 12,000 | $125.00 | $1,500,000.00 | |
| 1/9/2015 | Bruce I Sachs | Director | Sell | 9,861 | $125.04 | $1,233,019.44 | |
| 1/7/2015 | Joshua S Boger | Director | Sell | 10,500 | $119.32 | $1,252,860.00 | |
| 1/2/2015 | Jeffrey Chodakewitz | CMO | Sell | 2,291 | $122.54 | $280,739.14 | |
| 12/22/2014 | Joshua S Boger | Director | Sell | 10,500 | $117.65 | $1,235,325.00 | |
| 12/17/2014 | Joshua S Boger | Director | Sell | 10,500 | $110.66 | $1,161,930.00 | |
| 12/15/2014 | Jeffrey M Leiden | CEO | Sell | 50,017 | $114.97 | $5,750,454.49 | |
| 12/12/2014 | Paul M Silva | SVP | Sell | 2,813 | $120.08 | $337,785.04 | |
| 11/28/2014 | Amit Sachdev | EVP | Sell | 12,000 | $120.00 | $1,440,000.00 | |
| 11/28/2014 | Bruce I Sachs | Director | Sell | 10,000 | $120.03 | $1,200,300.00 | |
| 11/28/2014 | Paul M Silva | SVP | Sell | 8,164 | $119.85 | $978,455.40 | |
| 11/26/2014 | Joshua S Boger | Director | Sell | 10,500 | $114.54 | $1,202,670.00 | |
| 11/6/2014 | Bruce I Sachs | Director | Sell | 9,900 | $115.21 | $1,140,579.00 | |
| 11/5/2014 | Bruce I Sachs | Director | Sell | 30,100 | $112.62 | $3,389,862.00 | |
| 11/3/2014 | Joshua S Boger | Director | Sell | 127,411 | $112.20 | $14,295,514.20 | |
| 10/29/2014 | Joshua S Boger | Director | Sell | 10,500 | $109.44 | $1,149,120.00 | |
| 10/28/2014 | Amit Sachdev | EVP | Sell | 12,000 | $115.00 | $1,380,000.00 | |
| 10/28/2014 | David Altshuler | Director | Sell | 2,000 | $114.75 | $229,500.00 | |
| 10/28/2014 | Jeffrey Chodakewitz | CMO | Sell | 3,438 | $115.00 | $395,370.00 | |
| 10/27/2014 | Paul M Silva | SVP | Sell | 1,125 | $110.03 | $123,783.75 | |
| 10/13/2014 | Paul M Silva | SVP | Sell | 1,125 | $107.89 | $121,376.25 | |
| 10/7/2014 | Jeffrey Chodakewitz | CMO | Sell | 3,436 | $104.26 | $358,237.36 | |
| 10/6/2014 | David Altshuler | Director | Sell | 1,405 | $109.75 | $154,198.75 | |
| 10/1/2014 | Elaine Ullian | Director | Sell | 5,000 | $107.74 | $538,700.00 | |
| 10/1/2014 | Stuart A Arbuckle | EVP | Sell | 12,417 | $107.71 | $1,337,435.07 | |
| 9/30/2014 | Amit Sachdev | SVP | Sell | 86,000 | $112.68 | $9,690,480.00 | |
| 9/30/2014 | Ian F Smith | CFO | Sell | 108,026 | $112.68 | $12,172,369.68 | |
| 9/30/2014 | Jeffrey M Leiden | CEO | Sell | 200,000 | $112.69 | $22,538,000.00 | |
| 9/30/2014 | Kenneth L Horton | EVP | Sell | 36,000 | $112.69 | $4,056,840.00 | |
| 9/29/2014 | David Altshuler | Director | Sell | 2,500 | $114.75 | $286,875.00 | |
| 9/24/2014 | Joshua S Boger | Director | Sell | 5,200 | $109.21 | $567,892.00 | |
| 9/19/2014 | David Altshuler | Director | Sell | 5,000 | $102.25 | $511,250.00 | |
| 9/19/2014 | Paul M Silva | SVP | Sell | 25,408 | $99.85 | $2,536,988.80 | |
| 9/19/2014 | Stuart A Arbuckle | EVP | Sell | 55,521 | $100.00 | $5,552,100.00 | |
| 9/17/2014 | Joshua S Boger | Director | Sell | 5,200 | $93.62 | $486,824.00 | |
| 9/10/2014 | Joshua S Boger | Director | Sell | 5,200 | $94.42 | $490,984.00 | |
| 9/5/2014 | David Altshuler | Director | Sell | 2,500 | $94.75 | $236,875.00 | |
| 9/3/2014 | Joshua S Boger | Director | Sell | 5,200 | $92.79 | $482,508.00 | |
| 8/27/2014 | Joshua S Boger | Director | Sell | 5,200 | $93.31 | $485,212.00 | |
| 8/20/2014 | Joshua S Boger | Director | Sell | 5,200 | $91.51 | $475,852.00 | |
| 8/13/2014 | Joshua S Boger | Director | Sell | 5,200 | $88.00 | $457,600.00 | |
| 8/6/2014 | Joshua S Boger | Director | Sell | 5,200 | $86.54 | $450,008.00 | |
| 7/31/2014 | David Altshuler | Director | Sell | 5,000 | $89.59 | $447,950.00 | |
| 7/31/2014 | Paul M Silva | SVP | Sell | 2,027 | $88.97 | $180,342.19 | |
| 7/30/2014 | Joshua S Boger | Director | Sell | 5,200 | $92.17 | $479,284.00 | |
| 7/15/2014 | Wayne Joseph Riley | Director | Sell | 4,800 | $96.65 | $463,920.00 | |
| 7/1/2014 | Elaine Ullian | Director | Sell | 5,000 | $95.21 | $476,050.00 | |
| 7/1/2014 | Kenneth L Horton | EVP | Sell | 30,134 | $95.22 | $2,869,359.48 | |
| 6/24/2014 | Megan E Pace | SVP | Sell | 12,734 | $98.03 | $1,248,314.02 | |
| 6/24/2014 | Wayne Joseph Riley | Director | Sell | 15,000 | $98.03 | $1,470,450.00 | |
| 6/16/2014 | Peter Mueller | EVP | Sell | 7,500 | $68.31 | $512,325.00 | |
| 6/9/2014 | Elaine Ullian | Director | Sell | 2,500 | $75.00 | $187,500.00 | |
| 5/14/2014 | Peter Mueller | EVP | Sell | 7,500 | $67.45 | $505,875.00 | |
| 5/2/2014 | Megan Pace | SVP | Sell | 1,000 | $67.62 | $67,620.00 | |
| 4/15/2014 | Peter Mueller | EVP | Sell | 7,500 | $61.63 | $462,225.00 | |
| 4/9/2014 | Elaine Ullian | Director | Sell | 2,500 | $70.00 | $175,000.00 | |
| 3/21/2014 | Bruce Sachs | Director | Sell | 8,700 | $74.59 | $648,933.00 | |
| 3/17/2014 | Peter Mueller | EVP | Sell | 7,500 | $78.29 | $587,175.00 | |
| 2/7/2014 | Jeffrey Leiden | CEO | Sell | 35,944 | $80.00 | $2,875,520.00 | |
| 1/22/2014 | Bruce Sachs | Director | Sell | 8,300 | $84.47 | $701,101.00 | |
| 1/21/2014 | Megan Pace | SVP | Sell | 1,250 | $85.00 | $106,250.00 | |
| 1/16/2014 | Jeffrey Leiden | CEO | Sell | 45,000 | $80.00 | $3,600,000.00 | |
| 1/15/2014 | Peter Mueller | EVP | Sell | 7,500 | $78.67 | $590,025.00 | |
| 12/23/2013 | Bruce Sachs | Director | Sell | 8,300 | $73.02 | $606,066.00 | |
| 12/16/2013 | Peter Mueller | EVP | Sell | 7,500 | $64.69 | $485,175.00 | |
| 12/12/2013 | Jeffrey Leiden | CEO | Sell | 9,834 | $65.48 | $643,930.32 | |
| 12/12/2013 | Kenneth Horton | EVP | Sell | 4,532 | $65.46 | $296,664.72 | |
| 12/12/2013 | Megan Pace | SVP | Sell | 5,083 | $65.48 | $332,834.84 | |
| 12/4/2013 | Joshua Boger | Director | Sell | 1,400 | $67.48 | $94,472.00 | |
| 11/25/2013 | Joshua Boger | Director | Sell | 1,400 | $66.89 | $93,646.00 | |
| 11/20/2013 | Bruce Sachs | Director | Sell | 8,300 | $65.28 | $541,824.00 | |
| 11/19/2013 | Joshua Boger | Director | Sell | 1,400 | $62.31 | $87,234.00 | |
| 11/5/2013 | Joshua Boger | Director | Sell | 1,400 | $65.64 | $91,896.00 | |
| 10/29/2013 | Joshua S Boger | Director | Sell | 1,400 | $75.42 | $105,588.00 | |
| 10/29/2013 | Thomas Connolly | SVP | Sell | 1,688 | $75.04 | $126,667.52 | |
| 10/24/2013 | Bruce I Sachs | Director | Sell | 8,300 | $77.06 | $639,598.00 | |
| 10/23/2013 | Joshua S Boger | Director | Sell | 1,400 | $76.77 | $107,478.00 | |
| 10/16/2013 | Joshua S Boger | Director | Sell | 1,400 | $75.41 | $105,574.00 | |
| 10/15/2013 | Peter Mueller | EVP | Sell | 7,500 | $73.25 | $549,375.00 | |
| 10/14/2013 | Paul Silva | SVP | Sell | 1,593 | $71.87 | $114,488.91 | |
| 10/9/2013 | Joshua Boger | Director | Sell | 1,400 | $72.35 | $101,290.00 | |
| 9/25/2013 | Joshua Boger | Director | Sell | 1,400 | $74.72 | $104,608.00 | |
| 9/18/2013 | Joshua Boger | Director | Sell | 1,400 | $77.43 | $108,402.00 | |
| 9/16/2013 | Peter Mueller | EVP | Sell | 7,500 | $77.22 | $579,150.00 | |
| 9/11/2013 | Joshua Boger | Director | Sell | 1,400 | $79.61 | $111,454.00 | |
| 9/4/2013 | Joshua Boger | Director | Sell | 1,400 | $75.45 | $105,630.00 | |
| 8/29/2013 | Bruce Sachs | Director | Sell | 8,300 | $77.19 | $640,677.00 | |
| 8/28/2013 | Joshua Boger | Director | Sell | 1,400 | $76.24 | $106,736.00 | |
| 8/21/2013 | Joshua Boger | Director | Sell | 1,400 | $76.96 | $107,744.00 | |
| 8/15/2013 | Peter Mueller | EVP | Sell | 7,500 | $77.41 | $580,575.00 | |
| 8/14/2013 | Joshua Boger | Director | Sell | 1,400 | $77.18 | $108,052.00 | |
| 8/7/2013 | Joshua Boger | Director | Sell | 1,400 | $77.84 | $108,976.00 | |
| 8/5/2013 | Paul Silva | SVP | Sell | 3,001 | $78.90 | $236,778.90 | |
| 7/31/2013 | Joshua S Boger | Director | Sell | 1,400 | $80.89 | $113,246.00 | |
| 7/29/2013 | Wayne Joseph Riley | Director | Sell | 9,800 | $80.09 | $784,882.00 | |
| 7/25/2013 | Paul M Silva | SVP | Sell | 1,125 | $86.49 | $97,301.25 | |
| 7/24/2013 | Bruce I Sachs | Director | Sell | 8,300 | $85.50 | $709,650.00 | |
| 7/19/2013 | Amit Sachdev | SVP | Sell | 22,250 | $88.69 | $1,973,352.50 | |
| 7/18/2013 | Joshua S Boger | Director | Sell | 1,400 | $86.12 | $120,568.00 | |
| 7/16/2013 | Paul M Silva | SVP | Sell | 2,063 | $86.25 | $177,933.75 | |
| 7/15/2013 | Christiana Stamoulis | SVP | Sell | 1,125 | $86.35 | $97,143.75 | |
| 7/15/2013 | Peter Mueller | EVP | Sell | 7,500 | $86.34 | $647,550.00 | |
| 7/12/2013 | Megan E Pace | SVP | Sell | 10,678 | $85.00 | $907,630.00 | |
| 7/11/2013 | Joshua S Boger | Director | Sell | 1,400 | $83.83 | $117,362.00 | |
| 7/8/2013 | Kenneth L Horton | EVP | Sell | 1,813 | $80.72 | $146,345.36 | |
| 7/8/2013 | Megan E Pace | SVP | Sell | 28,703 | $80.89 | $2,321,785.67 | |
| 7/5/2013 | Christiana Stamoulis | SVP | Sell | 4,687 | $81.21 | $380,631.27 | |
| 7/3/2013 | Joshua S Boger | Director | Sell | 1,400 | $80.20 | $112,280.00 | |
| 7/2/2013 | Peter Mueller | EVP | Sell | 122,300 | $79.80 | $9,759,540.00 | |
| 6/26/2013 | Joshua S Boger | Director | Sell | 1,400 | $78.59 | $110,026.00 | |
| 6/21/2013 | Bruce I Sachs | Director | Sell | 8,300 | $75.93 | $630,219.00 | |
| 6/19/2013 | Joshua S Boger | Director | Sell | 1,400 | $79.11 | $110,754.00 | |
| 6/12/2013 | Joshua S Boger | Director | Sell | 1,400 | $81.19 | $113,666.00 | |
| 6/5/2013 | Joshua S Boger | Director | Sell | 1,400 | $77.15 | $108,010.00 | |
| 5/30/2013 | Joshua S Boger | Director | Sell | 1,400 | $82.47 | $115,458.00 | |
| 5/22/2013 | Joshua S Boger | Director | Sell | 1,400 | $79.72 | $111,608.00 | |
| 5/15/2013 | Joshua S Boger | Director | Sell | 1,400 | $79.36 | $111,104.00 | |
| 5/14/2013 | Bruce I Sachs | Director | Sell | 60,000 | $81.15 | $4,869,000.00 | |
| 12/26/2012 | Joshua S Boger | Director | Sell | 4,000 | $41.86 | $167,440.00 | |
| 11/7/2012 | Margaret G Mcglynn | Director | Buy | 1,000 | $45.50 | $45,500.00 | |
| 10/8/2012 | Ian F Smith | CFO | Sell | 44,787 | $60.00 | $2,687,220.00 | |
| 10/3/2012 | Joshua S Boger | Director | Sell | 4,000 | $57.74 | $230,960.00 | |
| 9/5/2012 | Joshua S Boger | Director | Sell | 4,000 | $54.70 | $218,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
| Source: |
|
| Date | Headline |
|---|
 | Vertex Pharmaceuticals Incorporated (VRTX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - August 19 at 2:44 PM |
 | 3 Stocks That Could Put Alibaba's Returns to Shame
www.fool.com - August 16 at 8:28 AM |
 | ETFs with exposure to Vertex Pharmaceuticals, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 8:47 PM |
 | Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn't Worth the Risk - Investorplace.com
investorplace.com - August 15 at 8:07 AM |
| Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk
investorplace.com - August 14 at 11:35 AM |
| Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk
investorplace.com - August 14 at 11:06 AM |
 | Vertex Pharmaceuticals May Be Turning Some Major Corners
seekingalpha.com - August 14 at 8:18 AM |
| See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
finance.yahoo.com - August 11 at 8:58 PM |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 11 at 7:00 PM |
| Vertex Pharmaceuticals Inc
finance.yahoo.com - August 11 at 1:45 AM |
| IHS Markit Score downgrades Vertex Pharmaceuticals Inc to 64 out of 100, ranking positively in only one out of three available IHS Markit categories.
finance.yahoo.com - August 10 at 3:42 PM |
| Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher - Investorplace.com
investorplace.com - August 10 at 9:31 AM |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) SVP Paul M. Silva Sells 1,289 Shares
www.americanbankingnews.com - August 9 at 10:22 PM |
| Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Sells 4,250 Shares of Stock
www.americanbankingnews.com - August 9 at 8:24 PM |
| Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher
investorplace.com - August 8 at 9:18 PM |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - August 6 at 4:32 PM |
| Brokerages Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Post Quarterly Sales of $512.79 Million
www.americanbankingnews.com - August 6 at 7:18 AM |
| Paul M. Silva Sells 1,289 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock
www.americanbankingnews.com - August 4 at 8:40 PM |
| Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells 1,796 Shares of Stock
www.americanbankingnews.com - August 4 at 8:22 PM |
| Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Sells 2,330 Shares of Stock
www.americanbankingnews.com - August 4 at 8:22 PM |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CFO Sells $332,236.35 in Stock
www.americanbankingnews.com - August 4 at 8:22 PM |
| Insider Selling: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Sells 5,390 Shares of Stock
www.americanbankingnews.com - August 4 at 7:52 PM |
| Vertex Pharmaceuticals Incorporated (VRTX) Expected to Post Q3 2017 Earnings of $0.11 Per Share
www.americanbankingnews.com - August 4 at 7:16 AM |
| Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
www.fool.com - August 3 at 8:22 PM |
| Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock? 3 Pros, 3 Cons
investorplace.com - August 3 at 10:02 AM |
| Vertex’s latest FDA nod could boost sales by $150M: analyst
finance.yahoo.com - August 3 at 8:43 AM |
| Corporate News Blog - Vertex Pharma Announces Approval from the FDA For KALYDECO in More Than 600 Patients Suffering from Cystic Fibrosis
finance.yahoo.com - August 3 at 8:43 AM |
| Vertex Pharmaceuticals Incorporated (VRTX) SVP Sells $131,571.40 in Stock
www.americanbankingnews.com - August 2 at 8:52 PM |
| Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells 2,125 Shares of Stock
www.americanbankingnews.com - August 2 at 8:34 PM |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CEO Jeffrey M. Leiden Sells 11,063 Shares
www.americanbankingnews.com - August 2 at 7:44 PM |
| Vertex: A Jewel In The Biotech Space - Seeking Alpha
seekingalpha.com - August 2 at 8:34 AM |
| FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations
finance.yahoo.com - August 2 at 8:34 AM |
| Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017
finance.yahoo.com - August 2 at 8:34 AM |
| Cowen and Company Reaffirms Buy Rating for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
www.americanbankingnews.com - August 1 at 9:18 PM |
| Jefferies Group Research Analysts Cut Earnings Estimates for Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - July 31 at 7:03 AM |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Rating Lowered by TheStreet
www.americanbankingnews.com - July 30 at 7:53 PM |
| Vertex Pharmaceuticals Incorporated Chugs Along
finance.yahoo.com - July 29 at 8:31 AM |
| Vertex Pharmaceuticals: Looking East, West and to the Quants
finance.yahoo.com - July 28 at 9:46 AM |
| BMO Capital Markets Reaffirms Outperform Rating for Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - July 27 at 10:27 PM |
| Vertex Pharmaceuticals Incorporated (VRTX) Price Target Raised to $175.00
www.americanbankingnews.com - July 27 at 1:14 PM |
 | Earnings Reaction History: Vertex Pharmaceuticals Incorporated, 40.0% Follow-Through Indicator, 2.6% Sensitive - Nasdaq
www.nasdaq.com - July 27 at 9:19 AM |
| Vertex Pharmaceuticals’ Focus on Innovative Combination Regimens
finance.yahoo.com - July 27 at 9:19 AM |
| Investor Network: Vertex Pharmaceuticals Incorporated to Host Earnings Call
finance.yahoo.com - July 27 at 9:19 AM |
| Vertex Reports Second-Quarter 2017 Financial Results
finance.yahoo.com - July 27 at 9:19 AM |
| Vertex Pharma reports quarterly profit
finance.yahoo.com - July 27 at 9:19 AM |
| Vertex Pharma's quarterly profit beats estimates
finance.yahoo.com - July 27 at 9:18 AM |
| Vertex Sinks Late Despite Crushing Sales, Profit Expectations
finance.yahoo.com - July 27 at 9:18 AM |
| Vertex tops Street 2Q forecasts
finance.yahoo.com - July 27 at 9:18 AM |
| Edited Transcript of VRTX earnings conference call or presentation 26-Jul-17 9:15pm GMT
finance.yahoo.com - July 27 at 9:18 AM |
| Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Posts Earnings Results
www.americanbankingnews.com - July 26 at 9:14 PM |
Vertex Pharmaceuticals Incorporated (VRTX) Chart for Sunday, August, 20, 2017
